MedTrace Logo

XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation

NCT06936527 · Status: ENROLLING_BY_INVITATION · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2025-09-03

No results posted yet for this study

Summary

XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab for treatment of metastatic colorectal cancer patients with RAS mutation

Conditions

Interventions

BIOLOGICAL

Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI

XS-03 orally Bevacizumab intravenously FOLFOX intravenously FOLFIRI intravenously

BIOLOGICAL

Drug: XS-03

XS-03 orally

BIOLOGICAL

Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI

Bevacizumab intravenously FOLFOX intravenously FOLFIRI intravenously

Sponsors & Collaborators

  • NovaOnco Therapeutics Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-23
Primary Completion
2028-04-30
Completion
2028-07-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06936527 on ClinicalTrials.gov